TITLE

Bayer aims high for its 2009 targets

AUTHOR(S)
Williams, Dede; Watts, Mark
PUB. DATE
March 2007
SOURCE
ICIS Chemical Business;3/19/2007, Vol. 2 Issue 58, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reveals that after buying Schering, Bayer has lifted its 2009 targets for earnings, capital expenditure, and research and development. According to Chairman Werner Wenning, Bayer's management is targeting an underlying margin of 22% for earnings before interest, tax, depreciation and amortization (EBITDA) by 2009. An overview of the company's earnings from its diverse chemical operations and its planned expenditures beginning in 2007 is discussed.
ACCESSION #
24525155

 

Related Articles

  • Bayer's Schering buy good move. Williams, Dede // ICIS Chemical Business;12/4/2006, Vol. 1 Issue 46, p10 

    The article focuses on the statement by Bayer chairman Werner Wenning regarding the impact of the acquisition of German drug maker Schering by Bayer. The consolidation of Schering contributed strongly to the expansion of quarterly sales, and Wenning said the takeover will boost full-year...

  • Bayer Considers Doubling Its Investment in Latin America. Thurston, Charles // Chemical Market Reporter;07/19/99, Vol. 256 Issue 3, p9 

    Focuses on the plan of Bayer AG to double its investment in Latin America up to 2004. Comment from Werner Wenning, management board representative of the firm in Latin America; Details on the investment plan; Information on the operation of the company.

  • Bayer beats earnings forecast. Robinson, Simon // European Chemical News;8/22/2005, Vol. 83 Issue 2160, p7 

    Reports on the success of Bayer to beat its full year earnings growth expectation in the second quarter of 2005. Factors that contributed to the success of Bayer; Expected increase in the earnings of the company for the year; Views of chairman Werner Wenning on the second quarter performance of...

  • Bayer off to an excellent start in 2008.  // Paintindia;Apr2008, Vol. 47 Issue 4, p195 

    The article reports on Bayer Group which posted excellent results in the first quarter of 2008. Werner Wenning, Chairman of Bayer AG Management Board, says their carried over the previous year's positive trend in both sales and earnings and that strengthened their confidence for the year as a...

  • Bayer strengthens research and development pharmaceutical pipeline is well filled, with 50 projects currently in phases I to III of clinical testing.  // Chemical Business;Jan2009, Vol. 23 Issue 1, p76 

    The article discusses the plans of the Bayer Group to expand its research and development activities. Werner Wenning, chairman of the Board of Management, said that their budget for research and development is €2.8 billion, the biggest in the in the chemical and pharmaceutical sector in...

  • Schering cuts save €700m/year. Robinson, Simon; Williams, Dede // ICIS Chemical Business;6/26/2006, Vol. 1 Issue 25, p10 

    The article reports on the takeover of Schering by Bayer in June 2006. The takeover is considered the biggest and the most expensive deal in the company's history. At a joint news conference, Werner Wenning of Bayer rejected suggestions that Bayer had not moved fast enough to thwart Merck by...

  • Bayer Schering job cuts. William, Dede; Gibson, Jane // ICIS Chemical Business Americas;3/5/2007, Vol. 271 Issue 9, p13 

    This article reports that Schering is set to cut 950 jobs at its headquarters in Berlin, Germany by 2009. Werner Wenning, Bayer chairman, said the move is due to the merger between the pharmaceutical activities of Schering and Bayer. Wenning, who is also chairman of Bayer Schering Pharma's...

  • Wrap-up.  // Chemical Week;1/29/97, Vol. 159 Issue 4, p25 

    Announces the appointment of Werner Wenning to Bayer's board of management effective February 1, 1997.

  • Sale of Merck's Shares Paves Way for Bayer to Buy Schering. Young, Ian // Chemical Week;6/21/2006, Vol. 168 Issue 21, p8 

    The article reports on the agreement of Merck KGaA to sell its stake in Schering to Bayer. The agreement means that Bayer will have to pay almost €17 billion for Schering, compared with the €16.5 billion it had originally offered. Bayer also announced that it had filed a lawsuit in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics